Bioavailability of dyphylline and dyphylline-guaifenesin tablets in humans.
J Pharm Sci
; 74(3): 335-7, 1985 Mar.
Article
em En
| MEDLINE
| ID: mdl-4009445
ABSTRACT
A six-way-crossover bioavailability study was conducted with twelve healthy male volunteers to evaluate the relative bioavailability of three tablet formulations containing dyphylline and three tablet formulations containing dyphylline-guaifenesin. Each subject was administered two tablets of each product with greater than or equal to 3 d separating each dose. Blood samples were obtained just prior to each dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, and 10.0 h following each dose. An HPLC method was used to assay dyphylline in the serum. The mean tmax ranged from 0.6 to 1.0 h for the six products. The mean values for Cmax differed by 29%, and the AUC values differed by less than 8%. It was noted that the dyphylline-guaifenesin products exhibited a lower bioavailability than the products which only contained dyphylline. It was concluded that the three combination products were bioequivalent, as were the three dyphylline products.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Teofilina
/
Difilina
/
Guaifenesina
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Ano de publicação:
1985
Tipo de documento:
Article